12:51 PM
 | 
May 25, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AM-Pharma completes Phase II enrollment of recAP in AKI

AM-Pharma B.V. (Bunnik, the Netherlands) completed enrollment of 301 patients in the Phase II STOP-AKI trial of recAP (recombinant alkaline phosphatase) to treat sepsis-associated acute kidney injury (AKI). The double-blind, placebo-controlled, international trial...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >